Actavis, Inc. (NYSE:ACT)

CAPS Rating: 4 out of 5

The Company is engaged in the development, manufacture, marketing, sale and distribution of brand and off-patent pharmaceutical products.

Results 1 - 20 of 34 : 1 2 Next »

Recs

0
Member Avatar FrankoJames (93.69) Submitted: 11/28/2014 9:22:18 AM : Outperform Start Price: $261.28 ACT Score: +3.56

I like Botox. ACT, outperform with or without a dividend. I am not a doctor.

Recs

0
Member Avatar RugbyViking13 (88.59) Submitted: 9/23/2014 2:24:07 PM : Outperform Start Price: $242.77 ACT Score: +6.90

lexapro - you can never leave

Recs

0
Member Avatar Herbstmd (55.45) Submitted: 8/23/2014 5:37:14 PM : Underperform Start Price: $226.76 ACT Score: -15.81

Way overpriced. Buys up other successful companies, then fires everyone in them with any experience, keeping only the youngest most inexperienced staff. I think this will prove in the long run to be a serious weakness. Overbearing company culture that cares little for employees.

Recs

0
Member Avatar tripleking (54.39) Submitted: 6/17/2014 10:21:35 AM : Outperform Start Price: $213.00 ACT Score: +20.58

good stock

Recs

0
Member Avatar Classical (< 20) Submitted: 3/28/2014 4:51:43 PM : Outperform Start Price: $204.27 ACT Score: +21.47

Excellent management, has not missed earnings since 2006 when the company was formally known as Watson. Growing bottom line organically and continues to cherry pick M&A that makes sense. Snaps up branded drugs coming off patent for its favorably large generic portfolio. This will be 100 billion dollar market cap if management continues its track record. Obama-care benefits this company directly because it generic line is so vast.

The founder ( Dr. Choi) started the company out of his garage!

Recs

1
Member Avatar naughtyguy (32.25) Submitted: 3/13/2014 10:43:49 AM : Underperform Start Price: $215.20 ACT Score: -14.95

34 billion market cap! You have got to be kidding!

Recs

0
Member Avatar DugdaleTiki (43.25) Submitted: 3/3/2014 9:27:18 AM : Outperform Start Price: $213.00 ACT Score: +14.86

2014 Sabrient Pick

Recs

0
Member Avatar StewpotDrew (53.38) Submitted: 2/3/2014 12:13:39 AM : Outperform Start Price: $190.00 ACT Score: +25.99

Drugs.

Recs

0
Member Avatar subsurfacemapper (47.46) Submitted: 1/22/2014 11:47:04 PM : Outperform Start Price: $186.18 ACT Score: +32.35

high RS in ibd and high comp

Recs

0
Member Avatar 1russianguy (81.91) Submitted: 1/13/2014 2:38:49 PM : Outperform Start Price: $182.54 ACT Score: +34.58

Sabrient

Recs

0
Member Avatar 1picks (87.99) Submitted: 1/13/2014 2:24:18 PM : Outperform Start Price: $182.72 ACT Score: +34.51

Sabrient

Recs

0
Member Avatar manirg (71.30) Submitted: 12/24/2013 12:28:45 PM : Outperform Start Price: $164.50 ACT Score: +51.24

Undervalued growth stock

Recs

0
Member Avatar chris293 (84.24) Submitted: 10/24/2013 5:49:57 PM : Underperform Start Price: $146.30 ACT Score: -66.91

Some of these stocks I just do not understand. A lot of negatives, for example a minus ROI, among others? O.K. they made 6 cents.

Recs

0
Member Avatar djtp54 (< 20) Submitted: 9/8/2013 2:58:01 PM : Outperform Start Price: $137.40 ACT Score: +72.47

bought the stock when it was Watson Pharma its been my best performer and i like how its been working

Recs

0
Member Avatar jagad5 (< 20) Submitted: 8/14/2013 11:56:19 AM : Outperform Start Price: $138.04 ACT Score: +73.41

Current price implies a growth rate of 20% while historical growth rate has been 30%.

Recs

0
Member Avatar TerryHoodSr (53.85) Submitted: 1/4/2013 8:44:52 PM : Outperform Start Price: $85.01 ACT Score: +176.26

TP 95

Recs

0
Member Avatar naylorj (61.78) Submitted: 8/3/2012 3:22:58 PM : Outperform Start Price: $79.37 ACT Score: +192.27

EPS Ranking 99

Recs

1
Member Avatar bradford86 (99.72) Submitted: 1/14/2012 2:40:11 PM : Outperform Start Price: $62.79 ACT Score: +271.69

276. Watson Pharmaceuticals (NYSE: WPI) is down from $70 where it topped in 2011. At the present price of around $62, I think that there is a little upside here. Target: $63-$68. My 2012 EPS estimate is $5.60 which puts this at a P/E of 11.1 for a company growing at a double digit clip. Definately looks inexpensive here. Glad to see Bret agrees. I'll be playing CAPS points on this one.

http://beta.fool.com/bradford86/2012/01/14/price-market-part-42/

Recs

0
Member Avatar lting77 (71.25) Submitted: 10/31/2010 9:26:22 PM : Outperform Start Price: $46.85 ACT Score: +403.59

with the purchase of arrow group, is has acquire first to market atorvastatin and partial ownership of eden biodesign, bio generic firm

would not be surprise if teva acquires them after it's done w/ digesting ratiopharm

Recs

0
Member Avatar cashman79 (66.16) Submitted: 9/15/2010 9:55:36 AM : Outperform Start Price: $42.56 ACT Score: +451.49

watch

Results 1 - 20 of 34 : 1 2 Next »

Featured Broker Partners


Advertisement